Obesity Drug Developer Corxel to Go Public in US via SPAC Deal - Regional Media News

Obesity drug developer Corxel to go public in US via SPAC deal - Regional Media News

Oct 26 (Reuters) - Obesity drug developer Corxel Pharmaceuticals will go public in the US through a merger with special purpose acquisition company Amanat Acquisition Corp, the companies announced on Monday. • The success of newer weight-loss therapies has spurred a wave of investments by [...]

Corxel US and Amanat Acquisition Corp Announce Definitive Business Combination Agreement to Create Publicly Listed Obesity-Focused Biopharmaceutical Company

Combined company expected to advance differentiated oral obesity franchise led by CX11, a clinical-stage, once-daily oral small-molecule GLP-1 receptor agonist ('RA”), and CX12,...

Corxel to take oral GLP-1 public in the US via SPAC

For the second week in a row, a drug developer is going public via a special purpose acquisition company (SPAC), the blank-check vehicle that had faded out of favor but now appears ...

Corxel US and Amanat Acquisition Corp Announce Definitive Business Combination Agreement to Create Publicly Listed Obesity-Focused Biopharmaceutical Company - PressReach

Combined company expected to advance differentiated oral obesity franchise led by CX11, a clinical-stage, once-daily oral small-molecule GLP-1 receptor agonist (“RA”), and CX12, a preclinical oral small-molecule amylin receptor agonist. CX11 has demonstrated clinically meaningful weight loss and a generally favorable tolerability profile across Phase 2 obesity studies in the United States. Following an End-of-Phase … Continue reading "Corxel US …